Inclusion Criteria:

Controls

• Healthy male volunteers
• Non-pregnant, non-breastfeeding female volunteers
• 18-70 years old
• Able to provide written informed consent before participating in the study
• Able to communicate adequately with the investigator and to comply with the requirements for the entire study

Additional inclusion criteria for patients

• Symptoms of dyspepsia with rapid gastric emptying by scintigraphy

Exclusion Criteria:

Patients and controls

• Abdominal surgery other than appendectomy, cholecystectomy, tubal ligation or hysterectomy
• Clinical evidence of significant:
  • Ccardiovascular 
  • Respiratory 
  • Renal 
  • Hepatic 
  • Gastrointestinal
  • Hematological 
  • Neurological 
  • Psychiatric 
  • Other disease that may interfere with the objectives of the study and/or pose safety concerns 
• Medications that may alter gastrointestinal motility, e.g., antipressants, alpha adrenergic agonists, calcium channel or b blockers. 
• Stable dose of thyroxine will be permitted. 
• If it is clinically safe, antidepressants (e.g., nortrptyline, amitryptyline), which are often used at low doses to delay gastric emptying and/or reduce visceral sensitivity, will be discontinued in patients before the study
• Patients who have taken any investigational medications within the past 30 days
• Pregnant or breast-feeding females

Exclusion criteria for controls only

• Current symptoms of a functional gastrointestinal disorder assessed by questionnaire